Article Details

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study - Benzinga

Retrieved on: 2022-04-01 11:24:19

Tags for this article:

Click the tags to see associated articles and topics

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study - Benzinga. View article details on hiswai:

Excerpt

ARCA biopharma Inc (NASDAQ: ABIO) announced results from the ASPEN-COVID-19 Phase 2 trial evaluating rNAPc2, a specific inhibitor of tissue factor ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up